

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

### **中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **REDESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 30 June 2023, Ms. Chui Hoi Yam (徐海音) (alias 徐海瑛) (former name: 徐海英) (“**Ms. Chui**”) has been re-designated from an executive Director to a non-executive Director (the “**Redesignation**”). Ms. Chui will continue to devote her time to the Company and contribute her valuable skills and experience to the overall strategic development and long-term growth of the Group in her role as a non-executive Director.

The biographical details of Ms. Chui are set out below:

Ms. Chui, aged 56, was appointed as an executive Director on 5 December 2022 and re-designated as a non-executive Director with effect from 30 June 2023. Prior to joining the Group, Ms. Chui was a president of Harbin Pharmaceutical Group Co., Ltd.\* (哈藥集團股份有限公司) (“**Harbin Pharmaceutical**”), a company listed on the Shanghai Stock Exchange (stock code: 600664), from March 2019 to May 2022 and was a director of Harbin Pharmaceutical from January 2021 to May 2022, where she was responsible for the overall business operation. Ms. Chui previously worked in China Hewlett-Packard Co., Ltd. and Novartis International.

Ms. Chui received her bachelor’s degree in economic administration and master’s degree in finance from Peking University, the People’s Republic of China in July 1990 and July 2001, respectively.

In respect of the Redesignation, Mr. Chui has entered into a new letter of appointment with the Company as a non-executive Director for a term of one year commencing from 30 June 2023 and is subject to retirement by rotation and re-election and other related provisions as stipulated in the bye-laws of the Company and the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”). Pursuant to the bye-laws of the Company, Ms. Chui shall be subject to retirement by rotation at least once every three years. Ms. Chui is entitled to a director’s fee of HK\$50,000 per month, which was determined by the Board on the recommendation of the remuneration committee of the Company with reference to her duties and responsibilities, as well as the prevailing market conditions.

As at the date of this announcement, Ms. Chui holds share options to subscribe for 5,000,000 shares of the Company. Details of the grant of share options to Ms. Chui are set out in the Company’s announcements dated 6 January 2023 and 10 January 2023.

As at the date of this announcement, save as disclosed above, Ms. Chui (i) does not hold any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, nor any other major appointments and professional qualifications; (ii) does not hold any other positions with the Company or other members of the Group; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (having the meaning ascribed to it in the GEM Listing Rules) of the Company; (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) has not been involved in any of the matters as mentioned under Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules.

Save as disclosed in this announcement, there is no further information relating to the Redesignation that would require disclosure under Rule 17.50(2) of the GEM Listing Rules and there are no other matters relating to the Redesignation that need to be brought to the attention of the shareholders of the Company.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 30 June 2023

*As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun and Mr. Huang Song; one non-executive Director, namely Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*

*\* for identification purpose only*